Kiromic BioPharma, Inc. Attends WSGR 3rd Healthcare Innovations Venture Investment Forum
Houston, Texas, Dec. 8, 2017 – Kiromic Inc., today announced that it has accepted an invitation to attend the Wilson Sonsini Goodrich & Rosati (WSGR) 3rd Healthcare Innovations Venture Investment Forum. During the event Kiromic conducted meetings with multiple investor firms. Kiromic was represented at the event by Dr. Maurizio Chiriva (CEO), Dr. Scott Dahlbeck (COO), Dr. Zahra Timsah (Vice President of Operations), and Dr. Jonathan Berrout (Director of Marketing). The forum was held on December 6th – 8th in Austin, Texas.
About Kiromic Biopharma
Kiromic is a clinical-stage immunotherapy biopharmaceutical company with a breakthrough artificial intelligence drug discovery platform (KAI), and a focus on therapeutic development across multiple technology platforms; including cell therapy, TCR therapy, and CAR-T therapy, oral immunotherapy, and gene therapy.
Kiromic is committed to developing effective immunotherapeutics to improve outcomes and dramatically improve patient’s lives.
For more information, visit www.kiromic.com.
About WSGR Healthcare Innovations Venture Investment Forum
The investment forum is a closed event, for confirmed investors and companies selected to participate, organized by WSGR Professional Corporation. The WSGR Corporation is a premier provider of legal services to technology, life sciences, and growth enterprises worldwide.
For more information, visit www.wsgr.com.